the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to over 33 million infections and 1.000.000 deaths worldwide [1]. Compared to other coronavirus outbreaks (SARS-CoV-1, MERS-CoV), SARS-CoV-2 is characterized by a higher basic reproductive rate and an overall lower mortality [2]. However, while coronavirus disease 2019 (COVID-19) typically begins as an infection of the upper aerodigestive tract, it may progress to severe forms, with an acute respiratory distress syndrome (ARDS) and a multisystemic disease.COVID-19 ARDS shares the common histological hallmarks with other infectious/non-infectious ARDS. Unspecific diffuse alveolar damage (DAD), as its histologic correlate, is characterized by edema, hemorrhage and intra-alveolar fibrin deposition, but in case of COVID-19 ARDS, also by a distinct angiocentric lymphocytic inflammation [3][4][5]. DAD is the leading pattern of lung injury and has been shown to be independent of mechanical ventilation. There is some evidence for alternative injury patterns in COVID-19 ARDS, such as acute fibrinous organizing pneumonia (AFOP). Nonetheless, COVID-19-induced DAD is by far the most frequently reported one and is also characterized by more distinct morphologic features, including vascular changes [5].In that, the detection of SARS-CoV-2 in multiple organs (respiratory tract, heart, endothelium, digestive tract, kidneys, brain) and multisystemic clinical features, suggest that COVID-19 might be a systemic "vascular disease" (Fig.